A new Covid variant, NB.1.8.1, raises alarms for its potential to spread rapidly and evade antibodies. Meanwhile, the FDA approves a long-lasting HIV injection, and concerns about public safety arise with ICE's rule changes.
A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
The FDA has approved lenacapavir, a groundbreaking antiviral drug for HIV prevention developed by biochemist Wesley Sundquist. Learn how this drug could change the future of HIV treatment and prevention.
A groundbreaking HIV prevention shot, Yeztugo, has been approved by the FDA, offering hope for at-risk individuals with its twice-yearly injections. However, concerns about cost and accessibility remain.
The FDA has approved Gilead's Yeztugo, a twice-yearly injection that could revolutionize HIV prevention, boasting a 99.9% effectiveness. While hailed as a breakthrough, concerns over pricing remain, with activists urging for affordability.
Kraft Heinz announces a major move to remove all artificial food dyes from U.S. products by 2027, focusing on natural alternatives. This decision aims to enhance food safety and address health concerns linked to synthetic dyes.
Merck's new drug ENFLONSIA has received FDA approval for preventing RSV in newborns and infants, promising significant reductions in hospitalizations and severe respiratory illness. This long-acting monoclonal antibody offers hope for parents facing RSV season challenges.
In a groundbreaking move, the FDA has approved Moderna's lower-dose Covid-19 vaccine for older adults and at-risk individuals. Get ready for a new option this fall as Moderna targets the LP.8.1 variant!
The U.S. has approved Moderna's new COVID-19 vaccine, mNexspike, specifically for high-risk groups. This innovative option offers a lower dose while maintaining effectiveness, marking a pivotal step in the fight against coronavirus.
In a groundbreaking achievement, scientists have developed the first gene-editing medicine tailored for a baby suffering from a rare DNA condition. After successful treatments, KJ Muldoon is now healthier and ready to go home, showcasing a promising future for gene therapies.
